ReviewBritish journal of pharmacology2022
The role of glia in the physiology and pharmacology of glucagon-like peptide-1: implications for obesity, diabetes, neurodegeneration and glaucoma.
Review in British journal of pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07030621 (Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke), which is not on this map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- GLP-1 receptor agonists in eye disease: a comprehensive review of current research and future potential.BMC ophthalmology · 2026 · on this mapPooled it
- Ocular disorders during treatment with GLP-1 receptor agonists: a systematic review and meta-analysis of observational studies.Frontiers in pharmacology · 2026Pooled it
- Glucagon-Like Peptide 1 Receptor Agonists and Age-Related Macular Degeneration Incidence.Ophthalmology. Retina · 2026Article
- Research Progress of Diabetes-related Glaucoma: Mechanisms, Impacts and Management Strategies.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Review
- Semaglutide Alleviates LPS-Induced Cognitive Disorder via O-GlcNAcylation of AKT-mTOR Signaling Pathway Components.Neuromolecular medicine · 2026Article
- Beyond Glycemic Control: Ocular Effects of Glucagon-like Peptide-1 Receptor Agonists.Vision (Basel, Switzerland) · 2026Review
- Therapeutic potential for glial-derived octadecaneuropeptide in the treatment of obesity.Expert opinion on therapeutic targets · 2026Article
- Glucagon-like Peptide-1 Receptor Agonists and Ocular Disease: Mechanisms, Evidence and Therapeutic Perspectives.International journal of molecular sciences · 2026Review
- Semaglultide targets Spp1Journal of neuroinflammation · 2025Article
- Association between various dosage forms of semaglutide and ocular adverse events in a real-world setting.BMC ophthalmology · 2025Article
- Novel Trajectories Towards Possible Effects of Semaglutide for Amelioration of Reserpine-induced Fibromyalgia in Rats: Contribution of cAMP/PKA/p-CREB and M1/M2 Microglia Polarization.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025Article
- Review
- Exploring the multifaceted roles of GLP-1 receptor agonists; a comprehensive review.Frontiers in clinical diabetes and healthcare · 2025Review
- Single-cell RNA sequencing advances in revealing the development and progression of MASH: the identifications and interactions of non-parenchymal cells.Frontiers in molecular biosciences · 2025Review
- Association Between Glucagon-Like Peptide-1 Receptor Agonists Exposure and Intraocular Pressure Change: GLP-1 Receptor Agonists and Intraocular Pressure Change.American journal of ophthalmology · 2025Article
- From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists.Molecular biology reports · 2024Review
- All GLP-1 Agonists Should, Theoretically, Cure Alzheimer's Dementia but Dulaglutide Might Be More Effective Than the Others.Journal of clinical medicine · 2024Review
- Special Issue "Pathophysiology and Treatment of Alzheimer's Disease".International journal of molecular sciences · 2024Article
- Stress, Allostatic Load, and Neuroinflammation: Implications for Racial and Socioeconomic Health Disparities in Glaucoma.International journal of molecular sciences · 2024Review
- From Liver to Brain: How MAFLD/MASLD Impacts Cognitive Function.Medical science monitor : international medical journal of experimental and clinical research · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The medical applications of glucagon-like peptide-1 receptor (GLP-1R) agonists is evergrowing in scope, highlighting the urgent need for a comprehensive understanding of the mechanisms through which GLP-1R activation impacts physiology and behaviour. A new area of research aims to elucidate the role GLP-1R signalling in glia, which play a role in regulating energy balance, glycemic control, neuroinflammation and oxidative stress. Once controversial, existing evidence now suggests that subsets of glia (e.g. microglia, tanycytes and astrocytes) and infiltrating macrophages express GLP-1Rs. In this review, we discuss the implications of these findings, with particular focus on the effectiveness of both clinically available and novel GLP-1R agonists for treating metabolic and neurodegenerative diseases, enhancing cognition and combating substance abuse. LINKED ARTICLES: This article is part of a themed issue on GLP1 receptor ligands (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.4/issuetoc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.